LifeStance CTO sells 42,067 shares at $12.87

Available on EDGAR 09/04/2026 - 04:52 PM EDT Accepted by SEC EDGAR 09/04/2026 - 04:51 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

LifeStance Health Group, Inc. (LFST) reported that Chief Technology Officer Vukasin Paunovich sold 42,067 shares of common stock on September 2, 2026 in a sale characterized as an open market or private transaction at a weighted average price of $12.87 per share, with individual trades ranging from $12.86 to $12.905. After this transaction, he directly owned 205,379 shares of LifeStance common stock.

Insider Trade Summary

Net Seller: 42,067 shares

Net Sell 1 txn

Insider Paunovich Vukasin

Role Chief Technology Officer

Sold 42,067 shs ($541K)

Type	Security	Shares	Price	Value
Sale	Common Stock F1	42,067	$12.87	$541K

Holdings After Transaction: Common Stock — 205,379 shares (Direct)

Footnotes (1)

1. F1. The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $12.86 to $12.905 inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Key Figures

Shares sold: 42,067 shares Weighted average sale price: $12.87 per share Sale price range: $12.86–$12.905 per share +2 more

5 metrics

Shares sold 42,067 shares Common stock sale on September 2, 2026 by Chief Technology Officer

Weighted average sale price $12.87 per share Average price across multiple sale transactions on September 2, 2026

Sale price range $12.86–$12.905 per share Range of individual trade prices within the reported sale

Shares owned after transaction 205,379 shares Direct ownership of Vukasin Paunovich following the sale

Net shares sold 42,067 shares Net effect of reported transactions in this Form 4

Key Terms

weighted average price, open market or private transaction, Form 4

3 terms

weighted average price financial

"The price reported is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

open market or private transaction financial

"Sale in open market or private transaction"

Form 4 regulatory

"insider transaction reported on Form 4"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did LifeStance Health Group (LFST) report?

LifeStance reported that its Chief Technology Officer, Vukasin Paunovich, sold 42,067 shares of common stock on September 2, 2026 in a transaction classified as a sale in an open market or private transaction.

At what price were the LFST shares sold in this Form 4 filing?

The shares were sold at a weighted average price of $12.87 per share. According to the disclosure, individual trades occurred in a price range from $12.86 to $12.905 per share.

How many LifeStance (LFST) shares does Vukasin Paunovich own after the sale?

Following the reported transaction, Vukasin Paunovich directly owns 205,379 shares of LifeStance Health Group, Inc. common stock.

Was the LFST insider sale under a Rule 10b5-1 trading plan?

No. The filing indicates the Rule 10b5-1 trading plan checkbox is not affirmed, and the only footnote explains the weighted average price and trade price range, without referencing any trading plan.

Who is the insider involved in the latest LFST Form 4 filing?

The insider is Vukasin Paunovich, who serves as Chief Technology Officer of LifeStance Health Group, Inc. He reported a sale of 42,067 shares of the company’s common stock.

How many LFST shares were sold in total in this transaction?

The transaction reported the sale of 42,067 shares of LifeStance Health Group, Inc. common stock in multiple trades on September 2, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Paunovich Vukasin

(Last) (First) (Middle)

C/O LIFESTANCE HEALTH GROUP, INC.

4800 N. SCOTTSDALE ROAD, SUITE 2500

(Street)

SCOTTSDALE ARIZONA 85251

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
LifeStance Health Group, Inc. [ LFST ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Technology Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/02/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/02/2026		S		42,067(1)	D	$12.87	205,379	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $12.86 to $12.905 inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

	By: /s/ Ryan Pardo, Attorney-in-Fact	09/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)